[1] Yang, C.F.; Liu, L.M.; Dong, Y.G. Chin. J. Heal. Insp. 2011, 18, 128-129. [2] Yang, S.J. Gansu Soc. Sci. 2005, 6, 239-240. [3] Zhang, M. Ph.D. thesis, Shaanxi University. 2008. [4] Liu, Y.J. Ph.D. thesis, Huazhong University of Science and Technology. 2009. [5] WHO. Indicators for Monitoring National Drug Policies. Geneva: WHO. 1999, 108. [6] WHO. How to Investigate Drug Use in Health Facilities. Geneva: WHO. 1993, 35. [7] WHO. Measuring Medicine Prices, Availability, Affordability and Price Components. Geneva: WHO. 2003, 22. [8] Jing, Z. China Pub. Admin. 2003, 3, 12-13. [9] Guo, Q.; Wang, S.; Wang, X.H. Chin. General Prac. 2002, 5, 888-889. [10] Hu, M.; Chen, Q.J.; Wu, P. Chin. Pharm. 2010, 21, 685-687. [11] Du, J.L.; Li, Y.Y.; Chen, X.M. Henan J. Prev. Med. 2007, 18, 82-84. [12] GAO. FDA Faces Challenges Meeting its Growing Medical Product Responsibilities and Should Develop Complete Estimates of its Resource Needs. Washington: GAO. 2009, 17. [13] GAO. Comprehensive Assessment of Staffing, Facilities and Equipment Needs. Washington: GAO. 1989, 9. [14] GAO. Opportunities Exist to better Address Management Challenges. Washington: GAO. 2010, 6. [15] Hu, Y.L. J. Pub. Admin. 2011, 2, 70-94. [16] GAO. Challenges for FDA in Conducting Manufacturer Inspections. Washington: GAO. 2008, 11. [17] GAO. Better Data Management and more Inspections are Needed to Strengthen FDA’s Foreign Drug Inspection Program. Washington: GAO. 2008, 15. [18] GAO. FDA’s Food Advisory and Recall Process Needs Strengthening. Washington: GAO. 2012, 22. [19] GAO. FDA’s Premarket Review and Post Market Safety Efforts. Washington: GAO. 2011, 5. [20] Peng, G.F.; Li, D.C.; Sheng, M.K. China Soft Sci. 2004, 6, 136-139. [21] Saaty, Thomas. Decision Making for Leaders: the Analytic Hierarchy Process for Decisions in a Complex World. PA: RWS Publications. 1990, 29. [22] Wu, S.L.; Lv, J.; Guo, S.L. Sci. Sci. Magmt. S&T. 2010, 4, 7-13. |